Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency

• Status: Completed
• Trial end date: 2014-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is conducted in Japan. The aim of this observational study is to evaluate the long-term safety and efficacy of activated recombinant human factor VII (NovoSeven®) in subjects with congenital FVII deficiency.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S

Criteria

Inclusion Criteria:

• Congenital FVII deficiency

• Never been treated with NovoSeven® before

• Patients already in treatment with NovoSeven®

Exclusion Criteria:

• History of hypersensitivity to any of the components in NovoSeven®